**Background of FGFBP1 Antibody**
The Fibroblast Growth Factor Binding Protein 1 (FGFBP1) is a secreted chaperone protein that binds to fibroblast growth factors (FGFs), modulating their bioavailability and interaction with receptors. Primarily expressed in tissues like the kidney, placenta, and certain tumors, FGFBP1 plays a role in angiogenesis, wound healing, and tumor progression by enhancing FGF-mediated signaling pathways. Dysregulation of FGFBP1 has been implicated in cancers, including squamous cell carcinoma and hepatocellular carcinoma, where it promotes cell proliferation, invasion, and metastasis.
FGFBP1 antibodies are essential tools for studying the protein's expression, localization, and function in both physiological and pathological contexts. These antibodies are widely used in techniques such as Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to detect FGFBP1 in tissue samples or cell lines. Researchers also employ FGFBP1 antibodies to investigate its role in tumor microenvironments, stromal interactions, and potential as a biomarker or therapeutic target.
Recent studies highlight FGFBP1's dual role in cancer—acting as either an oncogene or tumor suppressor depending on context—underscoring the need for reliable antibodies to dissect its complex biology. Commercial FGFBP1 antibodies are typically raised in rabbits or mice, targeting specific epitopes of the protein, and are validated for specificity and reproducibility across applications. Their development continues to support advances in understanding FGF signaling and cancer mechanisms.